News & Updates

Treatment with the combination of ribociclib plus binimetinib appears to be well tolerated and delivers modest clinical activity in patients with locally advanced or metastatic melanoma harbouring NRAS mutation, according to the results of a phase Ib/II study.

In patients with colorectal cancer (CRC), the survival gap between older and younger patient can largely be attributed to deaths during the first year after resection, a recent study has found.

High blood pressure (BP) levels do not appear to be an important risk factor for prostate cancer development and death, a study reports.

In the final analysis of the phase III ICON8* study, a weekly dose-dense chemotherapy (CT) regimen comprising paclitaxel and carboplatin did not improve survival outcomes in women with epithelial ovarian cancer** compared with the standard first-line (1L) paclitaxel-carboplatin regimen given once every 3 weeks (Q3W).

Use of pembrolizumab helps maintain or improve health-related quality of life in patients with previously treated, advanced endometrial cancer characterized by high levels of microsatellite instability (MSI) or deficient mismatch repair (MSI-H/dMMR), according to data from the phase II KEYNOTE-158 study.

Patients with renal tumours who have undergone laparoscopic partial nephrectomy (LPN) have shown similar surgical and oncologic outcomes as those treated with open partial nephrectomy (OPN), reports a study.

For bladder cancer patients scheduled to undergo radical cystectomy, the presence of mood and/or anxiety disorders may lead to a longer length of hospital stay and increase the likelihood of discharge to a nonhome facility, a study reports.

Treatment with cetuximab plus cisplatin 30 mg/m2 and radiotherapy appears safe and well tolerated in women with cervical carcinoma, a study has shown. In addition, fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) has exhibited early evidence of response to neoadjuvant cetuximab.